Microba Life Sciences Valuation Multiples

Microba Life Sciences is valued at $24M as of October 2026, a 1.9x revenue multiple. In the last 12 months, Microba Life Sciences revenue was $11M and Microba Life Sciences EBITDA was ($7M).

Microba Life Sciences Overview

About Microba Life Sciences

Microba Life Sciences is an Australian precision microbiome company based in Brisbane that sells clinical gut microbiome tests and supplements and holds a pipeline of microbiome-based therapeutic candidates. It was founded in 2017 as a University of Queensland spin-out by Professors Gene Tyson and Philip Hugenholtz and listed on the Australian Securities Exchange on 5 April 2022. Its main product, MetaXplore, is a gastrointestinal test sold to clinicians in Australia and the United Kingdom, where it bought the Invivo Healthcare testing and supplements business in December 2023. Group revenue was A$15.7 million in the year to June 2025, up 30 per cent, and the net loss was A$14.9 million. Sonic Healthcare is its largest shareholder and a distribution partner for its tests. Microba transferred its research services unit to Clinical Microbiomics in late 2024 and paused internal research and development in the 2025 financial year to look for partners for its therapeutic assets. In 2026 it agreed commercial terms for a proposed all-scrip merger with Genetic Signatures.


Founded

2017

HQ

Australia

Employees

52

Financials (LTM)

Revenue: $11M
EBITDA: ($7M)

EV

$22M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Microba Life Sciences Financials

Microba Life Sciences reported last 12-month revenue of $11M and negative EBITDA of ($7M).

In the same LTM period, Microba Life Sciences generated $6M in gross profit, ($7M) in EBITDA losses, and had net loss of ($13M).

Revenue (LTM)


Microba Life Sciences P&L

In the most recent fiscal year, Microba Life Sciences reported revenue of $11M and EBITDA of ($8M).

Microba Life Sciences is unprofitable as of last fiscal year, with gross margin of 47%, EBITDA margin of (70%), and net margin of (95%).

See analyst estimates for Microba Life Sciences
LTMLast FY202320242025202620272028
Revenue$11M$11M$6M$10M$11M
Gross Profit$6M$5M$3M$5M$5M
Gross Margin51%47%49%48%48%
EBITDA($7M)($8M)($11M)($10M)($8M)
EBITDA Margin(64%)(70%)(171%)(105%)(75%)
EBIT Margin(82%)(157%)(269%)(185%)(131%)
Net Profit($13M)($10M)($12M)($13M)($13M)
Net Margin(111%)(95%)(186%)(126%)(118%)
Net Debt-($6M)---

Financial data powered by Morningstar, Inc.

Microba Life Sciences Stock Performance

Microba Life Sciences has current market cap of $24M, and enterprise value of $22M.

Market Cap Evolution


Microba Life Sciences' stock price is $0.03.

Microba Life Sciences share price decreased by 1.0% in the last 30 days, and by 34.2% in the last year.

Microba Life Sciences has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Microba Life Sciences
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$22M$24M-0.0%-1.0%0.4%-34.2%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Microba Life Sciences Valuation Multiples

Microba Life Sciences trades at 1.9x EV/Revenue multiple, and (3.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Microba Life Sciences

EV / Revenue (LTM)


Microba Life Sciences Financial Valuation Multiples

As of October 5, 2026, Microba Life Sciences has market cap of $24M and EV of $22M.

Microba Life Sciences has a P/E ratio of (1.9x).

LTMLast FY202320242025202620272028
EV/Revenue1.9x2.0x3.5x2.2x2.0x
EV/EBITDA(3.0x)(2.8x)(2.0x)(2.1x)(2.7x)
EV/EBIT(2.3x)(1.3x)(1.3x)(1.2x)(1.5x)
EV/Gross Profit3.8x4.2x7.1x4.5x4.2x
P/E(1.9x)(2.4x)(2.1x)(1.9x)(1.9x)
EV/FCF(2.0x)(2.0x)(1.7x)(1.7x)(1.7x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Microba Life Sciences Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Microba Life Sciences Margins & Growth Rates

Microba Life Sciences decreased revenue by 3% but EBITDA grew by 9% in the last fiscal year.

In the most recent fiscal year, Microba Life Sciences reported gross margin of 47%, EBITDA margin of (70%), and net margin of (95%).

See estimated margins and future growth rates for Microba Life Sciences

Microba Life Sciences Margins

Last FY202420252026202720282029
Gross Margin47%48%48%52%
EBITDA Margin(70%)(105%)(75%)(52%)
EBIT Margin(157%)(185%)(131%)(65%)
Net Margin(95%)(126%)(118%)(89%)
FCF Margin(98%)(126%)(116%)(77%)

Microba Life Sciences Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(3%)59%8%14%
Gross Profit Growth1%55%8%22%
EBITDA Growth9%(3%)(23%)(20%)
EBIT Growth(35%)9%(24%)(44%)
Net Profit Growth43%7%1%(14%)
FCF Growth29%(1%)(0%)(25%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Microba Life Sciences Operational KPIs

Microba Life Sciences' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.

Microba Life Sciences' Rule of 40 is (38%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Microba Life Sciences' Rule of X is (18%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Microba Life Sciences
LTMLast FY202320242025202620272028
Rule of 40(29%)(38%)---
Bessemer Rule of X23%(18%)---
Revenue per Employee-$0.2M---
Opex per Employee-$0.4M---
S&M Expenses to Revenue-4%8%5%4%
G&A Expenses to Revenue-3%6%4%3%
R&D Expenses to Revenue-13%115%46%13%
Opex to Revenue-205%318%233%214%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Microba Life Sciences Competitors

Microba Life Sciences competitors include Genedrive, Optimi Health, Genematrix, Pathkey.AI, LSL Pharma Group, BCAL Diagnostics, Helyx Industries, Sona Nanotech, Rhythm Biosciences and Nexsen.

Most Microba Life Sciences public comparables operate across Laboratory Services, Life Sciences Tools, Diagnostics & Genomics, BioTech and DeepTech.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Genedrive$1M($7M)24.8x-(3.5x)-
Optimi Health$300K($2M)67.4x42.5x(12.8x)-
Genematrix$8M($1M)1.7x-(11.6x)-
Pathkey.AI$19K($949K)1044.8x-(21.2x)-
LSL Pharma Group$20M$2M3.0x-38.1x-
BCAL Diagnostics$15K($4M)1728.7x14.0x(5.9x)-
Helyx Industries$2M($2M)9.4x6.3x(13.8x)(27.7x)
Sona Nanotech-($2M)--(16.4x)-

This data is available for Pro users. Sign up to see all Microba Life Sciences competitors and their valuation data.

Start Free Trial

Microba Life Sciences VC Funding History

Before going public, Microba Life Sciences raised $31M in total equity funding, across 4 rounds.


Microba Life Sciences Funding Rounds

DateStageInvestorsRaisedValuationRev. MultipleDeal Summary
Jun-25Strategic investmentSonic Healthcare$9M-Sonic Healthcare, Microba Life Sciences' largest shareholder, took part in a A$14.5 million capital raising announced on 23 June 2025, investing about A$4.16 million in the first tranche of a A$12.5 million two-tranche placement at A$0.09 per share. That kept Sonic's voting power at 19.14 per cent after tranche 1, with a rise to 21.68 per cent expected after tranche 2 and a A$2.0 million fully underwritten share purchase plan. Subject to shareholder approval, Sonic was also to be issued an option with a total exercise price of about A$4.16 million (GBP 2 million) convertible into shares and options within 17 months, taking its total commitment to as much as A$8.3 million. Every two new shares carried one unlisted attaching option exercisable at A$0.14 for two years. Microba said the funds would drive clinical adoption of its core microbiome testing products in Australia and the United Kingdom and strengthen working capital, and it separately signed an exclusive laboratory processing agreement with Sonic's UK subsidiary The Doctors Laboratory. Microba's board and management committed about A$290,000 on the same terms, and pro forma cash at 31 March 2025 after the raising was expected to be A$26.29 million. Microba is a Brisbane gut microbiome diagnostics company founded in 2017.
Nov-22Strategic investmentSonic Healthcare$12M-Sonic Healthcare agreed on 29 November 2022 to invest A$17.8 million to acquire a 19.99 per cent stake in Microba Life Sciences. Sonic subscribed for new fully paid ordinary shares at A$0.26 per share, a 25 per cent premium to the five-day volume weighted average price, within Microba's existing placement capacity. Sonic also sought unlisted options exercisable at A$0.33 over a further 5 per cent, subject to shareholder approval at a general meeting, which would have meant a further A$7.5 million if exercised. Alongside the investment the companies agreed initial terms of a strategic alliance under which Sonic and its subsidiaries would distribute Microba's microbiome tests, exclusively for one year from 31 January 2023 in Germany, Belgium and the United Kingdom and non-exclusively in Switzerland, the United States, Australia and New Zealand. Sonic's chief medical officer, Dr Stephen Fairy, joined Microba's medical advisory board, and Sonic did not seek a board seat. Microba said the proceeds would advance its therapeutic programs and support international expansion of its testing services, and its pro forma cash at 30 September 2022 after the deal was A$43.8 million. Microba is a Brisbane precision microbiome company founded in 2017 that had listed on the ASX in April 2022.
Jun-19Strategic investmentMicrogen Plc$3M--
Apr-18Series AAlium Capital$7M-Microba Life Sciences is a microbiome analysis company founded in 2017 by Philip Hugenholtz and Gene Tyson, based in Brisbane, Australia. The company specializes in gut microbiome testing services, offering the Microba Insight Sampling Kit to consumers, healthcare practitioners, and researchers, alongside a Metagenomic Analysis Platform (MAP) for research studies. The company received a Series A investment from Alium Capital in 2018. By 2022, following its ASX IPO which raised $30 million, Microba reported revenue of $4.68 million and had $30.5 million in cash. The company has partnered with synthetic biology leader Ginkgo Bioworks (which made a $3.5 million strategic investment) and International Flavours & Fragrances to develop novel allergy treatments, while advancing its therapeutic development program, including the MAP 315 candidate for ulcerative colitis treatment.

Acquisitions by Microba Life Sciences

Microba Life Sciences has acquired 1 company to date.

Last acquisition by Microba Life Sciences was on October 19th 2023. Microba Life Sciences acquired Invivo Healthcare for $14M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Microba Life Sciences

Invivo Healthcare
Description
Invivo Healthcare is a United Kingdom-based supplier of nutritional therapeutics and laboratory diagnostics. Headquartered in Sevenoaks, Kent, it distributes practitioner-only formulas for gut health, hormones, and detoxification alongside testing kits for allergies, hormones, and microbiome analysis. Products reach clinics, hospitals, and wellness centers across Europe.
HQ CountryUnited Kingdom
HQ City
Stroud
Deal Date19 Oct 2023
Valuation$14M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Microba Life Sciences acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Microba Life Sciences

When was Microba Life Sciences founded?Microba Life Sciences was founded in 2017.
Where is Microba Life Sciences headquartered?Microba Life Sciences is headquartered in Australia.
How many employees does Microba Life Sciences have?As of today, Microba Life Sciences has over 52 employees.
Is Microba Life Sciences publicly listed?Yes, Microba Life Sciences is a public company listed on Australian Securities Exchange.
What is the stock symbol of Microba Life Sciences?Microba Life Sciences trades under MAP ticker.
When did Microba Life Sciences go public?Microba Life Sciences went public in 2022.
Who are competitors of Microba Life Sciences?Microba Life Sciences main competitors include Genedrive, Optimi Health, Genematrix, Pathkey.AI, LSL Pharma Group, BCAL Diagnostics, Helyx Industries, Sona Nanotech, Rhythm Biosciences, Nexsen.
What is the current market cap of Microba Life Sciences?Microba Life Sciences' current market cap is $24M.
What is the current revenue of Microba Life Sciences?Microba Life Sciences' last 12 months revenue is $11M.
What is the current revenue growth of Microba Life Sciences?Microba Life Sciences revenue growth (NTM/LTM) is 35%.
What is the current EV/Revenue multiple of Microba Life Sciences?Current revenue multiple of Microba Life Sciences is 1.9x.
Is Microba Life Sciences profitable?No, Microba Life Sciences is not profitable.
What is the current EBITDA of Microba Life Sciences?Microba Life Sciences has negative EBITDA and is not profitable.
What is Microba Life Sciences' EBITDA margin?Microba Life Sciences' last 12 months EBITDA margin is (64%).
What is the current EV/EBITDA multiple of Microba Life Sciences?Current EBITDA multiple of Microba Life Sciences is (3.0x).
What is the current FCF of Microba Life Sciences?Microba Life Sciences' last 12 months FCF is ($11M).
What is Microba Life Sciences' FCF margin?Microba Life Sciences' last 12 months FCF margin is (95%).
What is the current EV/FCF multiple of Microba Life Sciences?Current FCF multiple of Microba Life Sciences is (2.0x).
How many companies Microba Life Sciences has acquired to date?As of October 2026, Microba Life Sciences has acquired 1 company.
What was the largest acquisition by Microba Life Sciences?$14M acquisition of Invivo Healthcare on 19th October 2023 was the largest M&A Microba Life Sciences has done to date.
What companies Microba Life Sciences acquired?Microba Life Sciences acquired Invivo Healthcare.
In how many companies Microba Life Sciences has invested to date?Microba Life Sciences hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Microba Life Sciences

Lists including Microba Life Sciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial